Lurasidone for schizophrenia

Current Psychiatry

Volumn 10, Issue 1, 2011, Pages 67-70

  Lincoln, Jana ^a   Tripathi, Aveekshit ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; DOPAMINE 2 RECEPTOR; KETOCONAZOLE; LURASIDONE; OLANZAPINE; PLACEBO; RIFAMPICIN; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 7 RECEPTOR;

AGITATION; AKATHISIA; ANXIETY DISORDER; ARTICLE; DIZZINESS; DRUG ABSORPTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; DYSPEPSIA; DYSTONIA; HUMAN; INSOMNIA; MAXIMUM PLASMA CONCENTRATION; NAUSEA; ORTHOSTATIC HYPOTENSION; PARKINSONISM; QT PROLONGATION; SCHIZOPHRENIA; SEIZURE; SIDE EFFECT; SOMNOLENCE; VOMITING; WEIGHT GAIN;

EID: 79952081850     PISSN: 15378276     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Latuda [package insert]. Marlborough, MA: Sunovion Pharmaceuticals, Inc.; 2010.
2. Meyer JM, Loebel AD, Schweizer E. Lurasidone: a new drug in development for schizophrenia. Expert Opin Investig Drugs. 2009;18(11):1715-1726.
3. Terry AV Jr, Buccafusco JJ, Wilson C. Cognitive dysfunction in neuropsychiatric, disorders: selected serotonin receptor subtypes as therapeutic targets. Behav Brain Res. 2008;195(1):30-38.
4. th Annual Meeting; December 5-9, 2010; Miami Beach, FL.
5. nd Annual Meeting of American Psychiatric Association; May 16-21, 2009; San Francisco, CA. Abstract NR1-054.
6. Nakamura M, Ogasa M, Guarino J, et al. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry. 2009;70(6):829-836.
7. th Annual Meeting of American College of Neuropsychopharmacology; December 6-10, 2009; Hollywood, FL. Abstract 76.